Participant Engagement and Symptom Improvement: Aripiprazole Tablets with Sensor for the Treatment of Schizophrenia

PURPOSE: A recent, phase 3b, mirror-image clinical trial of outpatients with schizophrenia found that use of aripiprazole tablets with sensor (AS; Abilify MyCite(®), comprising an ingestible event-marker sensor embedded in aripiprazole tablets, wearable sensor patches, and a smartphone application)...

Descripción completa

Detalles Bibliográficos
Autores principales: Cochran, Jeffrey M, Fang, Hui, Le Gallo, Christophe, Peters-Strickland, Timothy, Lindenmayer, Jean-Pierre, Reuteman-Fowler, J Corey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9342879/
https://www.ncbi.nlm.nih.gov/pubmed/35923658
http://dx.doi.org/10.2147/PPA.S362889

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9342879/
https://www.ncbi.nlm.nih.gov/pubmed/35923658
http://dx.doi.org/10.2147/PPA.S362889

Ejemplares similares